NASDAQ$RNAM

Avidity Biosciences Inc · Q3 2023 earnings

Q3 2023 earnings · · Investor relations

Headline financials

Total Revenue

$2.82M

Previous: $2.48M+13.5%
EPS (adj)

-$0.71

Previous: -$0.82+13.4%
Capital Expenditures

-$3.37M

Previous: -$1.97M-70.6%
Free Cash Flow

-$139M

Previous: -$99.1M-40.3%
Net Income

-$52.4M

Previous: -$43.6M-20.1%
Operating Income

-$58.6M

Previous: -$44.9M-30.5%
Gross Profit

$0.00

Previous: $0.00
Cash & Equivalents

$543M

Previous: $144M+277.6%
Total Assets

$573M

Previous: $431M+33.1%
R&D Expense

$47.7M

No prior period
Stock-Based Comp

$9.82M

Previous: $7.09M+38.6%

Revenue & EPS history

Avidity Biosciences · Revenue · Quarterly

$2.82M

Q3 2023+13.5%vs Q3 2022
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Avidity Biosciences · $2.82M total across 1 segment · Q3 2023

  • Collaboration revenue
    $2.82M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 8 quarterly earnings reports

Historical avg

+1.3%

Avg return

Earnings day

+4.7%

Avg return

5 days after

+8.2%

Avg return

30 days after

55%

12 / 22 earnings

Positive

+19.5%

Q4 2023

Best reaction

-12.5%

Q1 2021

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026
Q4 2025
Q3 2025+1.3%+1.4%+2.5%
Q2 2025-2.7%-2.8%+6.1%
Q1 2025-0.6%+1.3%-2.0%
Q4 2024+5.4%+1.7%+11.9%
Q3 2024-1.1%-1.1%-18.9%
Q2 2024+6.2%+2.6%-2.9%
Q1 2024-0.4%+11.0%+2.2%
Q4 2023+19.5%+23.1%+66.6%
Q3 2023-6.0%
Q2 2023+6.0%
Q1 2023+4.0%
Q4 2022+5.6%
Q3 2022+5.7%
Q2 2022+0.2%
Q1 2022-9.4%
Q4 2021+0.9%
Q3 2021-0.5%
Q2 2021-1.4%
Q1 2021-12.5%
Q4 2020+7.5%
Q3 2020-1.0%
Q2 2020+1.9%
Q1 2020
Q4 2019
Q3 2019
Q2 2019
Q1 2019

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro